恒瑞医药：子公司收到注射用SHR-A2102临床试验批准通知书

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Heng Rui Medicine Co., Ltd. received approval from the National Medical Products Administration for the clinical trial of SHR-A2102, a targeted antibody-drug conjugate [1] Group 1 - SHR-A2102 is a self-developed drug targeting Nectin-4, with an effective payload of topoisomerase I inhibitor (TOP1i) [1] - Currently, there is only one similar product approved globally, Enfortumab vedotin (brand name: Padcev) [1]